Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
IWP 4 (HB3066)
Description:Potent Wnt/β-catenin signaling inhibitor. Induces cardiomyocyte differentiation of hESCs and iPSCs.
Purity:>98%
-
JK 184 (HB3179)
Description:Downstream Hedgehog signaling pathway inhibitor. Alcohol dehydrogenase 7 inhibitor.
Purity:>99%
-
-
Kenpaullone (HB1266)
Description:Potent CDK inhibitor. Also GSK-3 inhibitor. Generates iPSCs.
Purity:>98%
-
KY 02111 (HB3465)
Description:Wnt signaling inhibitor. Promotes differentiation of hESCs and iPSCs into cardiomyocytes.
Purity:>99%
-
LDN193189 hydrochloride (LDN) (HB5624)
Description:Potent, selective ALK2/ALK3 inhibitor which also promotes neural induction of hPSCs. May be used as a component for brain organoid production.
Purity:>98%
-
LY 294002 hydrochloride (HB2266)
Description:PI3-K inhibitor. Suppresses mESC proliferation.
Purity:>99%
-
-
Minocycline hydrochloride (HB4617)
Description:Broad spectrum antibiotic. Potent microglial activation inhibitor. Allows formation of EPSs.
Purity:>98%
